Globus Medical Stock News

International sales were down in the most recent quarter.

Geneva Capital Management LLC reduced its position in shares of Globus Medical, Inc. (NYSE:GMED) by 0.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,248,074 shares of the medical device companys stock after selling 8,452 shares during the period. Globus Medical accounts for []

Shares of Globus Medical, Inc. (NYSE:GMED) have received an average recommendation of “Buy” from the fourteen research firms that are covering the company, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average 1-year target price among brokers that have updated […]

Enabling tech is likely to continue driving Globus Medical Inc’s (NYSE: GMED) market share gains in 2022, according to BofA Securities. The Globus Medical Analyst: Craig Bijou upgraded the rating fo

Enabling tech is likely to continue driving Globus Medical Inc's (NYSE:GMED) market share gains in 2022, according to BofA Securities. The Globus Medical Analyst: Craig Bijou upgraded the rating for G

Royal Bank of Canada assumed coverage on shares of Globus Medical (NYSE:GMED) in a research note released on Thursday, The Fly reports. The brokerage issued an outperform rating and a $80.00 price target on the medical device company’s stock. Several other research analysts have also recently weighed in on GMED. Piper Sandler lowered their target […]

Globus Medical, Inc. (NYSE:GMED) was the target of a large decrease in short interest in November. As of November 15th, there was short interest totalling 782,200 shares, a decrease of 31.4% from the October 31st total of 1,140,000 shares. Based on an average daily volume of 463,800 shares, the days-to-cover ratio is presently 1.7 days. []

Robotic Surgery Market Snapshot 2021: The Robotic Surgery Market Study by StraitsResearch gives a vital tool and source to Industry stakeholders to figure out the market and other important technicalities, covering growth, market current and future opportunities, competitive scenarios, and top key trends in the

Prominent joint reconstruction devices manufacturers across the globe include Stryker, ConforMIS, Smith & Nephew, NuVasive, Medtronic, Globus Medical, Medacta, Zimmer Biomet, DJO Global, MicroPort Scientific Corporation, and Waldemar LINK. Prominent joint reconstruction devices manufacturers across the globe include Stryker, ConforMIS, Smith & Nephew, NuVasive, Medtronic, Globus Medical, Medacta, Zimmer Biomet, DJO Global, MicroPort Scientific Corporation, and Waldemar LINK.

Investors are optimistic about Globus Medical's (GMED) better-than-expected earnings and robust ExcelsiusGPS performance.

Investors are optimistic about Globus Medical's (GMED) better-than-expected earnings and robust ExcelsiusGPS performance.

Globus Medical (NYSE:GMED) issued an update on its FY 2021 earnings guidance on Thursday morning. The company provided EPS guidance of $2.000-$2.000 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.010. The company issued revenue guidance of $950 million-$950 million, compared to the consensus revenue estimate of $952.13 million. Shares of […]

In the superior Orthotic Devices market report, the whole and crystal clear outline of the Orthotic Devices market is penned down which is valuable for many businesses. The info covered in this consistent report helps businesses know how patents, licensing

Equities analysts expect Globus Medical, Inc. (NYSE:GMED) to report earnings per share of $0.48 for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Globus Medicals earnings. The highest EPS estimate is $0.52 and the lowest is $0.46. Globus Medical posted earnings of $0.58 per share during the same quarter []

Shares of Globus Medical, Inc. (NYSE:GMED) have been given a consensus recommendation of Buy by the thirteen brokerages that are presently covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 1 year price target among brokers that []